DelistingJul 30, 2026, 04:37 PM
Genprex Granted Nasdaq Listing Extension Until Dec 7, 2026
AI Summary
Genprex, Inc. announced that the Nasdaq Hearings Panel has granted its request to continue listing on The Nasdaq Capital Market. The company received an exception to the $1.00 Minimum Bid Price requirement, subject to strict conditions. Genprex must demonstrate compliance by July 29, 2026, and maintain a closing bid price at or above $1.00 until December 7, 2026, with the Panel retaining jurisdiction. The company acknowledges there is no assurance it will satisfy these terms or maintain compliance.
Key Highlights
- Nasdaq Hearings Panel granted Genprex an exception for continued listing.
- Company must demonstrate compliance with $1.00 minimum bid price by July 29, 2026.
- Must maintain a closing bid price at or above $1.00 until December 7, 2026.
- Nasdaq Panel will maintain jurisdiction over the Company until December 7, 2026.
- Company was previously notified of delisting for non-compliance with bid price rule.
- No assurance Genprex will satisfy the terms of the exception or maintain compliance.
Price Impact
More from GNPX